Advertisement
Screener

AMNEAL PHARMACEUTICALS, INC. (AMRX) Graph

AMRX Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $796.20M; Cost of revenue $461.69M; Research and development $39.02M; Selling, general and administrative $148.72M.
  • 2026-03-31: Revenue $722.52M; Cost of revenue $402.41M; Research and development $38.38M; Selling, general and administrative $138.86M.
  • 2025-12-31: Revenue $814.32M*; Cost of revenue $517.13M*; Research and development $34.82M*; Selling, general and administrative $146.46M*.
  • 2025-09-30: Revenue $784.51M; Cost of revenue $510.54M; Research and development $63.35M; Selling, general and administrative $137.81M.

Consolidation item

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

AMRX revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Corporate Non Segment$0.00Revenue$796.20MCost of revenue$461.69MGross profit$334.51MOperating income$129.77MOther income, net$653.00KResearch & development$39.02MSelling, general& administrative$148.72MPre-tax income$70.99MIncome tax$1.38M

Segment

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

AMRX revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.AffordableMedicines Segment$489.91MAv KARE Segment$156.99MSpecialty Segment$149.30MRevenue$796.20MCost of revenue$461.69MGross profit$334.51MOperating income$129.77MOther income, net$653.00KResearch & development$39.02MSelling, general& administrative$148.72MPre-tax income$70.99MIncome tax$1.38M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2026-06-30$796.20M$461.69M$39.02M$148.72M(m)$1.38M$57.66M
2026-03-31$722.52M$402.41M$38.38M$138.86M(m)$2.18M$62.26M
2025-12-31$814.32M*$517.13M*$34.82M*$146.46M*(m)$5.66M*$35.08M*
2025-09-30$784.51M$510.54M$63.35M$137.81M(m)-$23.36M$2.37M
2025-06-30$724.51M$438.25M$47.96M$124.27M(m)$16.10M$22.42M
2025-03-31$695.42M$439.53M$40.04M$118.29M(m)$12.87M$12.20M
2024-09-30$702.47M$432.91M$61.10M$118.69M(m)$3.67M-$156.00K
2024-06-30$701.78M$451.83M$36.05M$116.46M(m)$3.62M$5.99M
2024-03-31$659.19M$421.13M$39.30M$112.59M(m)$6.16M-$91.64M
2023-09-30$620.04M$387.51M$41.38M$113.01M(m)-$2.08M$9.68M
2023-06-30$599.05M$379.02M$37.80M$105.57M(m)-$23.00K$11.92M
2023-03-31$557.54M$379.35M$38.69M$102.10M(m)$668.00K-$6.94M
2022-09-30$545.56M$351.33M$50.23M$100.07M(m)$4.57M-$7.61M
2022-06-30$559.36M$358.84M$50.75M$98.81M(m)$7.35M-$242.13M
2022-03-31$497.63M$323.06M$52.80M$98.67M(m)-$3.46M-$8.82M
2021-09-30$528.59M$329.39M$48.93M$91.40M(m)$4.05M-$7.78M
2021-06-30$535.08M$322.58M$52.86M$86.16M(m)$2.65M$29.99M
2021-03-31$493.11M$301.54M$48.18M$90.73M(m)$359.00K$12.75M
2020-09-30$519.29M$353.35M$44.52M$83.12M(m)$144.00K-$21.64M
2020-06-30$464.66M$319.67M$45.57M$80.94M(m)$2.19M-$24.16M
2020-03-31$498.53M$313.58M$36.38M$77.98M(m)-$108.17M$120.43M
2019-12-31$397.33M(m)(m)(m)(m)(m)(m)
2019-09-30$378.28M$267.72M$38.13M$63.80M(m)$389.67M-$265.01M
2019-06-30$404.64M$296.38M$48.02M$67.28M(m)-$5.70M-$16.90M
2019-03-31$446.12M$309.74M$53.86M$84.44M(m)-$8.43M-$47.88M
2018-12-31$497.53M(m)(m)(m)(m)(m)(m)
2018-09-30$476.49M$268.57M$42.35M$75.49M(m)$5.11M$6.89M
2018-06-30$413.79M$235.49M$50.34M$56.00M(m)-$12.42M-$17.86M
2018-03-31$275.19M$130.59M$44.21M$25.12M$0.00$364.00K$0.00
2017-12-31$293.37M(m)(m)(m)$0.00$0.00(m)
2017-09-30$254.73M$119.72M$41.32M$27.44M(m)-$738.00K$0.00
2017-06-30$259.87M$136.14M$47.18M$26.94M(m)$1.85M$0.00
2017-03-31$225.68M(m)(m)(m)(m)(m)(m)

Revenue and expense 5 month

Period endNet income
2018-09-30-$32.33M

Revenue and expense 6 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeIncome taxNet income
2026-06-30$1.52B$864.10M$77.40M$287.58M$3.55M$119.92M
2025-06-30$1.42B$877.78M$88.00M$242.55M$28.97M$34.61M
2024-06-30$1.36B$872.96M$75.35M$229.06M$9.77M-$85.65M
2023-06-30$1.16B$758.38M$76.49M$207.67M$645.00K$4.97M
2022-06-30$1.06B$681.90M$103.55M$197.47M$3.89M-$250.94M
2021-06-30$1.03B$624.12M$101.05M$176.88M$3.01M$42.74M
2020-06-30$963.20M$633.24M$81.95M$158.92M-$105.99M$96.27M
2019-06-30$850.76M$606.12M$101.87M$151.72M-$14.13M-$64.78M
2018-06-30$688.98M$366.09M$94.54M$81.12M-$12.05M-$17.86M
2017-06-30$485.55M$245.80M$86.60M$54.64M$2.85M$0.00

Revenue and expense 9 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeIncome taxNet income
2025-09-30$2.20B$1.39B$151.36M$380.37M$5.61M$36.98M
2024-09-30$2.06B$1.31B$136.45M$347.75M$13.44M-$85.81M
2023-09-30$1.78B$1.15B$117.86M$320.67M-$1.43M$14.66M
2022-09-30$1.60B$1.03B$153.78M$297.54M$8.46M-$258.56M
2021-09-30$1.56B$953.51M$149.97M$268.28M$7.06M$34.96M
2020-09-30$1.48B$986.59M$126.47M$242.04M-$105.84M$74.63M
2019-09-30$1.23B$873.84M$140.00M$215.51M$375.54M-$329.79M
2018-09-30$1.17B$634.65M$136.89M$156.61M-$6.94M-$10.98M
2017-09-30$740.28M$365.52M$127.93M$82.08M$2.12M$0.00

Revenue and expense 12 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeIncome taxNet income
2025-12-31$3.02B$1.91B$186.18M$526.83M$11.28M$72.06M
2024-12-31$2.79B$1.77B$190.71M$476.44M$18.86M-$116.89M
2023-12-31$2.39B$1.57B$163.95M$429.68M$8.45M-$83.99M
2022-12-31$2.21B$1.43B$195.69M$399.70M$6.66M-$270.58M
2021-12-31$2.09B$1.32B$201.85M$365.50M$11.20M$13.16M
2020-12-31$1.99B$1.33B$179.93M$326.73M-$104.36M$67.79M
2019-12-31$1.63B$1.15B$188.05M$289.60M$383.33M-$603.57M
2018-12-31$1.66B$938.77M$194.19M$227.85M-$1.42M-$19.74M
2017-12-31$1.03B$507.48M$171.42M$109.05M$2.00M$0.00
2016-12-31$1.02B$420.77M$179.02M$118.76M$5.39M$0.00

Similar stocks

Stock NameCountryMarket CapPE Ratio
Liquidia Corp (LQDA)United States$6.347B51.23
RHYTHM PHARMACEUTICALS, INC. (RYTM)United States$6.771B-37.20
Alkermes plc. (ALKS)$6.844B132.74
Mirum Pharmaceuticals, Inc. (MIRM)United States$5.798B-8.81
Travere Therapeutics, Inc. (TVTX)United States$5.712B-123.10
Oruka Therapeutics, Inc. (ORKA)United States$5.663B-43.76
Cogent Biosciences, Inc. (COGT)United States$5.450B-17.61
IONIS PHARMACEUTICALS INC (IONS)United States$7.277B-23.25
Gossamer Bio, Inc. (GOSS)United States$5.355B-0.65
PTC THERAPEUTICS, INC. (PTCT)United States$5.199B-177.07